BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTIONS
The present disclosure relates to compositions of bacteriophages, and use of the same for medical and non-medical applications, in particular treatment of Pseudomonas infection.
1 . (canceled)
2 . (canceled)
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . (canceled)
10 . (canceled)
11 . (canceled)
12 . (canceled)
13 . (canceled)
14 . (canceled)
15 . (canceled)
16 . (canceled)
17 . (canceled)
18 . (canceled)
19 . (canceled)
20 . (canceled)
21 . (canceled)
22 . (canceled)
23 . (canceled)
24 . (canceled)
25 . (canceled)
26 . (canceled)
27 . (canceled)
28 . (canceled)
29 . (canceled)
30 . (canceled)
31 . (canceled)
32 . (canceled)
33 . (canceled)
34 . (canceled)
35 . (canceled)
36 . A method of treating a bacterial infection comprising administering a composition comprising one or more obligately lytic bacteriophage that infect and lyse Pseudomonas , the bacteriophage selected from: bacteriophage having at least 99% identity to a genomic sequence of Pa222 (deposited under ECACC reference no. 17062003), bacteriophage having at least 97% identity to a genomic sequence of Pa193 (deposited under ECACC reference no. 17062004), or bacteriophage having at least 97% identity to a genomic sequence of Pa204 (deposited under ECACC reference no. 17062006), wherein the composition is substantially free of bacterial components, to a subject.
37 . A method of treating a bacterial infection comprising:
a) selecting a patient with a confirmed Pseudomonas infection and,
b) administering a composition comprising one or more obligately lytic bacteriophage that infect and lyse Pseudomonas , the bacteriophage selected from: bacteriophage having at least 99% identity to a genomic sequence of Pa222 (deposited under ECACC reference no. 17062003), bacteriophage having at least 97% identity to a genomic sequence of Pa193 (deposited under ECACC reference no. 17062004), or bacteriophage having at least 97% identity to a genomic sequence of Pa204 (deposited under ECACC reference no. 17062006), wherein the composition is substantially free of bacterial components, to the subject.
38 . The method of claim 37 wherein the composition comprises a total of 1×10 5 to about 1×10 11 PFU.
39 . The method of claim 37 wherein the composition is administered every 6 hours.
40 . The method of claim 37 wherein the composition is administered every 12 hours.
41 . The method of claim 37 wherein the composition is administered for at least 7 days.
42 . The method according to claim 36 , wherein the bacterial infection is a sinus, nasal, lung, respiratory infection.
43 . The method according to claim 42 , wherein the bacterial infection is a urinary tract infection, intra-abdominal infection, skin infection, skin structure infection, or bacteremia.
44 . The method according to claim 42 , wherein the bacterial infection is a lung infection.
45 . The method according to claim 36 , wherein the bacterial infection is endocarditis.
46 . The method according to claim 36 , wherein the bacterial infection is an implant infection.
47 . The method according to claim 36 , wherein the bacterial infection is associated with cystic fibrosis.
48 . The method according to claim 36 , wherein the bacterial infection is resistant to antibiotics.
49 . The method according to claim 36 , wherein the bacterial infection is a Pseudomonas bacterial infection.
50 . The method according to 36 , wherein the bacterial infection is a Pseudomonas aeruginosa bacterial infection.
51 . (canceled)
52 . (canceled)
53 . A method of treating a lung infection comprising administering a composition comprising one or more obligately lytic bacteriophage that infect and lyse Pseudomonas , the bacteriophage selected from: bacteriophage having at least 99% identity to a genomic sequence of Pa222 (deposited under ECACC reference no. 17062003), bacteriophage having at least 97% identity to a genomic sequence of Pa193 (deposited under ECACC reference no. 17062004), or bacteriophage having at least 97% identity to a genomic sequence of Pa204 (deposited under ECACC reference no. 17062006), wherein the composition is substantially free of bacterial components, to a subject.
54 . The method according to claim 53 , wherein the lung infection is caused by a Pseudomonas bacterial infection.
55 . The method according to claim 54 , wherein the lung infection is caused by a Pseudomonas aeruginosa bacterial infection.
56 . The method according to claim 53 , further comprising administering an antibiotic and/or immunosuppressant to the subject.
57 . The method according to claim 56 , wherein the antibiotic is a fluoroquinolone, carbepenem, aminoglycoside, cephalosporin, penicillins, beta lactamase inhibitor, monobactams, phosphonic acids, or polymixins.
58 . The method according to claim 53 , wherein the composition is applied to the surface of the respiratory tract or lung tissue.
59 . The method according to claim 58 , wherein the application is done via an aerosolized formulation of the composition.
60 . The method according to claim 53 , wherein the composition is administered intravenously.
61 . (canceled)
62 . (canceled)
63 . (canceled)
64 . (canceled)
65 . (canceled)
66 . A method of killing bacteria on a surface, said method comprising applying a composition comprising one or more obligately lytic bacteriophage that infect and lyse Pseudomonas , the bacteriophage selected from: bacteriophage having at least 99% identity to a genomic sequence of Pa222 (deposited under ECACC reference no. 17062003), bacteriophage having at least 97% identity to a genomic sequence of Pa193 (deposited under ECACC reference no. 17062004), or bacteriophage having at least 97% identity to a genomic sequence of Pa204 (deposited under ECACC reference no. 17062006), wherein the composition is substantially free of bacterial components, to the surface.
67 . The method according to claim 66 , wherein the surface is the skin of a mammal, equipment, medical equipment, prostheses, implant, bedding, furniture, walls, floors, or combinations thereof.
68 . (canceled)
69 . (canceled)
70 . A method for manufacturing a bacteriophage composition, said method comprising admixing at least two bacteriophages selected from: Pa222, Pa193, and Pa204, and bacteriophage having at least 90% identity thereto.
71 . A method for manufacturing a bacteriophage composition, said method comprising admixing at least two bacteriophages having a genomic sequence selected from: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, and bacteriophage having at least 90% identity thereto.
72 . (canceled)
73 . The method of claim 71 , wherein the bacteriophage of the composition infect and lyse Pseudomonas.
74 . The method of claim 71 , wherein the bacteriophage of the composition infect and lyse Pseudomonas aeruginosa.